These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 15778581)

  • 1. A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro.
    Nayak T; Norenberg J; Anderson T; Atcher R
    Cancer Biother Radiopharm; 2005 Feb; 20(1):52-7. PubMed ID: 15778581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells.
    Nayak TK; Norenberg JP; Anderson TL; Prossnitz ER; Stabin MG; Atcher RW
    Nucl Med Biol; 2007 Feb; 34(2):185-93. PubMed ID: 17307126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy.
    Graf F; Fahrer J; Maus S; Morgenstern A; Bruchertseifer F; Venkatachalam S; Fottner C; Weber MM; Huelsenbeck J; Schreckenberger M; Kaina B; Miederer M
    PLoS One; 2014; 9(2):e88239. PubMed ID: 24516620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation.
    Nayak TK; Atcher RW; Prossnitz ER; Norenberg JP
    Nucl Med Biol; 2008 Aug; 35(6):673-8. PubMed ID: 18678352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.
    Kratochwil C; Giesel FL; Bruchertseifer F; Mier W; Apostolidis C; Boll R; Murphy K; Haberkorn U; Morgenstern A
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2106-19. PubMed ID: 25070685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
    Kulkarni HR; Schuchardt C; Baum RP
    Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors.
    Ugur O; Kothari PJ; Finn RD; Zanzonico P; Ruan S; Guenther I; Maecke HR; Larson SM
    Nucl Med Biol; 2002 Feb; 29(2):147-57. PubMed ID: 11823119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model.
    Norenberg JP; Krenning BJ; Konings IR; Kusewitt DF; Nayak TK; Anderson TL; de Jong M; Garmestani K; Brechbiel MW; Kvols LK
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):897-903. PubMed ID: 16467104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
    Schuchardt C; Kulkarni HR; Prasad V; Zachert C; Müller D; Baum RP
    Recent Results Cancer Res; 2013; 194():519-36. PubMed ID: 22918780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy.
    Chan HS; de Blois E; Morgenstern A; Bruchertseifer F; de Jong M; Breeman W; Konijnenberg M
    PLoS One; 2017; 12(7):e0181473. PubMed ID: 28732021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
    Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
    de Jong M; Breeman WA; Valkema R; Bernard BF; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():13S-7S. PubMed ID: 15653647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.
    Todorović-Tirnanić M; Kaemmerer D; Prasad V; Hommann M; Baum RP
    Recent Results Cancer Res; 2013; 194():487-96. PubMed ID: 22918778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
    Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
    J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
    Frilling A; Weber F; Saner F; Bockisch A; Hofmann M; Mueller-Brand J; Broelsch CE
    Surgery; 2006 Dec; 140(6):968-76; discussion 976-7. PubMed ID: 17188146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study.
    Eigler C; McDougall L; Bauman A; Bernhardt P; Hentschel M; Blackham KA; Nicolas G; Fani M; Wild D; Cordier D
    J Nucl Med; 2024 Apr; 65(4):573-579. PubMed ID: 38423782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.
    Barone R; Borson-Chazot F; Valkema R; Walrand S; Chauvin F; Gogou L; Kvols LK; Krenning EP; Jamar F; Pauwels S
    J Nucl Med; 2005 Jan; 46 Suppl 1():99S-106S. PubMed ID: 15653658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
    Förster GJ; Engelbach MJ; Brockmann JJ; Reber HJ; Buchholz HG; Mäcke HR; Rösch FR; Herzog HR; Bartenstein PR
    Eur J Nucl Med; 2001 Dec; 28(12):1743-50. PubMed ID: 11734910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms.
    Borgna F; Haller S; Rodriguez JMM; Ginj M; Grundler PV; Zeevaart JR; Köster U; Schibli R; van der Meulen NP; Müller C
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1113-1126. PubMed ID: 34625828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiproliferative effects of 111In- or 177Lu-DOTATOC on cells exposed to low multiplicity-of-infection double-deleted vaccinia virus encoding somatostatin subtype-2 receptor.
    Akinlolu O; Ottolino-Perry K; McCart JA; Reilly RM
    Cancer Biother Radiopharm; 2010 Jun; 25(3):325-33. PubMed ID: 20578838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.